Category Archives: Stem Cell Treatment


Looking to Mouse, Macaque and Human Germ Cells for New Insight into Infertility – University of Michigan Health System News

Figuring out how sperm develops in the testes is critical to understanding male-factor infertility. This process involves both the sperm-forming cells, collectively called germ cells, and supporting cells of the testis known as somatic cells. So far, much of the work around this highly regulated process, called spermatogenesis, has taken place in mice.

A group of U-M and University of Pittsburgh researchers, led by Sue Hammoud, Ph.D., Jun Li Ph.D., and Kyle Orwig Ph.D., and trainees Adrienne Shami, B.S., Xianing Zheng B.S., and Sarah Munyoki B.S., are expanding this body of knowledge by comparing cells from the testes of mice, macaques and humans. Using single-cell RNA sequencing, they analyzed the way genes are expressed in thousands of these sperm-forming cells to look for similarities and differences. This comparison provides clues about how sperm has evolved in mammals.

From the stem cell building blocks all the way up to mature sperm, there are differences between species in the number, division, and shape of germ cells. While we have learned a great deal from mouse models, sometimes that knowledge simply doesnt translate to humans. As a result, we have a limited understanding of human sperm production, and how things may go wrong to lead to infertility. By simultaneously analyzing thousands of cells throughout this process from different species, we are able to align and directly compare these populations of cells for the first time. In essence, this allows us to begin translating information across species to better understand how sperm are made, says Hammoud.

The findings could help researchers more accurately compare spermatogenesis between animal models and humans, with the ultimate goal of generating in vitro sperm to treat infertility.

Germ cells cant do it alone; they also require help from the neighboring somatic cells which provide signals and nutrients. While most research has focused on the Sertoli nurse cells or testosterone-producing Leydig cells, our study shows that many other underappreciated cell types could provide important input. Learning about these communications will be critical to identify and stimulate human cells in order to produce sperm as a future therapeutic option.

This work was supported by theMichigan Institute for Data Science, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and Open Philanthropy

Paper cited: Single-Cell RNA Sequencing of Human, Macaque, and Mouse Testes Uncovers Conserved and Divergent Features of Mammalian Spermatogenesis. Developmental Cell. DOI: 10.1016/j.devcel.2020.05.010

View post:
Looking to Mouse, Macaque and Human Germ Cells for New Insight into Infertility - University of Michigan Health System News

Stem Cell Therapy Market to Rise Globally During 2020-2027 with Top Key Players and Competitive Analysis – 3rd Watch News

Stem Cell Therapy

Stem Cell Therapy Market provides a birds eye view of the current proceeding within the Stem Cell Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Stem Cell Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Stem Cell Therapy market over the forecast period (2020-2027) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Leading Players Of Stem Cell Therapy Market:- MEDIPOST, Pharmicell Co., Inc., RichSource, BioTime Inc. (Lineage Cell Therapeutics, Inc.), Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., Caladrius Biosciences, Inc., TiGenix NV, AlloSource

Get Sample PDF Of Stem Cell Therapy Market @https://www.theinsightpartners.com/sample/TIPHE100000991/

Key Reasons to Purchase:

To gain insightful analyses of the Covid-19 Impact on Stem Cell Therapy market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact on the global Covid-19 Impact on Stem Cell Therapy market.

Learn about the Covid-19 Impact on Stem Cell Therapy market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

Stem Cell Therapy Market: Regional analysis includes:

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

Reasons to Purchase Stem Cell Therapy report is:

Gives a complete understanding of the Stem Cell Therapy Market to express competitor information, analysis, and insights to formulate effective RD strategies.

Collect data of the developing participants having the potentially profitable portfolio in this space and create effective counter-strategies to gain competitive benefits.

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure@https://www.theinsightpartners.com/buy/TIPHE100000991/

The research study can answer the following Key questions:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

For More Information Kindly Contact:Call: +1-646-491-9876

Email:[emailprotected]

More:
Stem Cell Therapy Market to Rise Globally During 2020-2027 with Top Key Players and Competitive Analysis - 3rd Watch News

FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure – Herald-Mail Media

BALTIMORE, June 4, 2020 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG34217, was approved on May 23, 2020. EXG34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure.

The FDA's approval allows Elixirgen Therapeutics to proceed with its planned Phase I/II, open label, single center clinical trial to assess the safety and tolerability of EXG34217 at Cincinnati Children's Hospital Medical Center (ClinicalTrials.gov Identifier: NCT04211714). This program's treatment paradigm uses Elixirgen Therapeutics' proprietary ZSCAN4 technology to extend the telomeres of the hematopoietic stem cells of the patients.

About Elixirgen Therapeutics, Inc.Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company co-founded by Akihiro Ko and Minoru Ko, MD, PhD, which is focused on curing humanity's ailments through innovations in stem cell biology.The company's experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. For more information visit https://ElixirgenTherapeutics.com

Forward-Looking StatementsThis press release may contain "forward-looking" statements, including statements regarding the effectiveness of EXG34217 to treat telomere biology disorders with bone marrow failure and statements relating to the planned clinical trials of EXG34217. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in drug research and development. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Elixirgen Therapeutics that its plans and objectives regarding EXG34217 will be achieved. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statementsin the future, even if new information becomes available.

Contact:Media RelationsElixirgen Therapeutics, Inc.(443) 869-5420Media@ElixirgenTherapeutics.com

Follow this link:
FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure - Herald-Mail Media

Global and United States Adipose Derived Stem Cell Therapy Market 2020 (Coronavirus (COVID-19) Business Impact and Analysis) | Research Industry – SG…

The report study researched by Research Industry US gives comprehensive knowledge and valuable insights about the Global and United States Adipose Derived Stem Cell Therapy Market. Also, the study attempts to deliver significant and detailed insights into the current market prospect and emerging growth scenarios. The report on the Global and United States Adipose Derived Stem Cell Therapy Market also emphasizes on market players as well as the new entrants in the market landscape.

Global and United States Adipose Derived Stem Cell Therapy Market is estimated to reach $XX billion in 2019 with a CAGR of XX% from 2019 to 2025.

Download Free Sample PDF Report (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Global and United States Adipose Derived Stem Cell Therapy Market @ http://researchindustry.us/report/global-and-united-states-adipose-derived-stem-cell-therapy-market-rie/546467/request-sample

The Global and United States Adipose Derived Stem Cell Therapy Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Adipose Derived Stem Cell Therapy Market Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Adipose Derived Stem Cell Therapy Market industry.

Impact of Coronavirus (COVID-19) on Global and United States Adipose Derived Stem Cell Therapy Market.

Coronavirus (COVID-19) is spreading across the world with a serious impact on the economy and the global market. The report considers and accounts for the impact of COVID-19 on Global and United States Adipose Derived Stem Cell Therapy Market across all the segments, regions, countries, and key players. North America and Europe are worst-hit countries by Coronavirus which are key players in the global economy. The report provides a detailed analysis of the impact on the market, growth strategies, supply china disruption, consumption pattern of the Global and United States Adipose Derived Stem Cell Therapy Market.

The report provides market size with 2019 as the base year in consideration and a yearly forecast until 2026 in terms of Revenue (USD Million). The estimates for all segments including type and application have been provided on a regional basis for the forecast period mentioned above. We have implemented a mix of top-down and bottom-up approaches for market sizing, analyzing the key regional markets, dynamics, and trends for various applications.

Browse Complete Report Description and Full TOC @ http://researchindustry.us/report/global-and-united-states-adipose-derived-stem-cell-therapy-market-rie/546467

The Global and United States Adipose Derived Stem Cell Therapy Market has been estimated by integrating the regional markets.

By Type:

Cells, Allogeneic Stem Cells, etc.

By Application:

Application, Research Application, etc.

Competitive Landscape:

Key players profile in the report include

Market segment by players, this report coversAlloCureMesoblastCelllerisAntriaIntrexonCelgene CorporationTissue GenesisCytori TherapeuticsCorestemPluristem TherapeuticsCyagenBioRestorative TherapiesLonzaPluristem TherapeuticsCelltex Therapeutics CorporationiXCells Biotechnologies

The report of Global and United States Adipose Derived Stem Cell Therapy Market studies the key players present in the market. The chapter includes the competitive landscape section which provides the full and in-depth analysis of the current market trends, changing technologies, and developments that will be beneficial for the companies, which are competing in the market. The report offers an overview of revenue, demand, and supply of data, futuristic cost, and growth analysis during the projected year. In addition to a brief overview of the company, analysts shed light on their valuation and evolution. It also discusses the list of important products and the ones in the pipeline. The competitive landscape is analyzed by understanding the approaches of the companies and the initiatives they have taken in recent years to triumph over the intensive competition.

A section of the report has given complete information about regional analysis. It provides a market outlook and positions the forecast within the context of the overall Global and United States Adipose Derived Stem Cell Therapy Market. Research Industry US has segmented the Global and United States Adipose Derived Stem Cell Therapy Market into major geographical regions such as North America, Europe, Asia Pacific, South America, and the Middle East and Africa. Potential new entrants desiring to target only high growth areas are also incorporated in this informative section of the Global and United States Adipose Derived Stem Cell Therapy Market.

Request Customization or Discount of This Report @ http://researchindustry.us/report/global-and-united-states-adipose-derived-stem-cell-therapy-market-rie/546467/request-customization

Report Objectives:

Get In Touch!Research IndustryNavale ICON IT Park,Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, PuneMaharashtra 411041Phone +1 213-275-4706Emailsales@researchindustry.us

David Barstow is a senior editor at SG Research Sphere covering products, apps, services, and consumer tech issues and trends. He is very active in social media and collects regular information for the company. He brings a great vision to the nexus of content and the social, digital, video and pragmatic network. He has eight years of experience with his expertise in conglomerate industries.

Go here to read the rest:
Global and United States Adipose Derived Stem Cell Therapy Market 2020 (Coronavirus (COVID-19) Business Impact and Analysis) | Research Industry - SG...

MSC Therapy for Acute Respiratory Distress Syndrome; It’s Time to Accelerate Clinical Trials for COVID-19 Patients in Need – P&T Community

WASHINGTON, June 3, 2020 /PRNewswire/ --A new systematic review and meta-analysis of clinical studies using mesenchymal stromal cells (MSCs) led by a team at the Mayo Clinic, and including researchers from Emory, Duke, Case-Western, and the University of Miami, shows a trend toward improved outcomes and reduced mortality for patients with acute respiratory distress syndrome (ARDS), a major complication for patients with COVID-19. This studyand several othersalso have shown that MSCs are safe for patients.

Based on these findings, the authors call for the rapid commencement of large-scale, confirmatory clinical trials to build on the existing evidence base, which shows a trend toward improved pulmonary function and reduced severe lung inflammation for patients with ARDS, paving the way toward another treatment option for seriously ill patients with COVID-19.

To date, nearly two million Americans have tested positive for COVID-19 and more than 100,000 Americans have died. In its most severe form, COVID-19 leads to ARDSa life-threatening lung injury that allows fluid to leak into the lungs and makes it difficult for patients to breathe. More than 40 percent of individuals hospitalized for severe and critical COVID-19 develop ARDS, and 22 percent to 62 percent of those who are diagnosed and become critically ill, die from the disease. There is no effective treatment for ARDS today; MSCs potentially offer a unique therapeutic option to help patients in need.

"The analysis shows a positive trend in outcomes when treating ARDS patients with MSC therapy and represents the potential to save thousands of patients with COVID-19 induced ARDS," said Wenchun Qu, MD, PhD of the Mayo Clinic and first author of the paper. "The potential benefitcombined with the demonstrated safety of these therapiessupports the need for rapid commencement of more clinical trials."

"Acute respiratory distress syndrome is a rapidly progressive disease that can occur in critically ill patients," said Anthony Atala, MD, Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "Having additional potential therapies, such as MSCs, could be highly beneficial to patients with COVID-19."

To date, the FDA has approved more than a dozen investigational new drug applications for the use of MSCs for COVID-19-related conditions. The National Institutes of Health (NIH) has also supported the use of MSCs and other regenerative cell therapies to help patients with other conditions. The bipartisan 21st Century Cures Act provided $30 million in funding to the NIH over three years for clinical research for such therapies. However, these limited investments expire in fiscal year 2020.

The Alliance for Cell Therapy Now and the Regenerative Medicine Foundation support the recommendation of the authors, who urge funding for larger studies that build on the results to date. Collaboration and funding are also needed to collect and analyze the evidence from multiple ongoing and new studies, to better evaluate outcomes and potential benefits of MSC therapy for COVID-19 patients in need. A portion of the more than $10 billion in funding directed by Congress to the Biomedical Advanced Research and Development Authority (BARDA) and the NIH for COVID-19 should be used to support these goals.

About the Alliance for Cell Therapy Now

Alliance for Cell Therapy Now (ACT Now) is an independent, non-profit organization devoted to advancing the availability of and access to safe and effective cell therapies for patients in need. ACT Now convenes experts and stakeholders to develop and advance sound policies that will improve the development, manufacturing, delivery, and improvement of regenerative cell therapies. See http://allianceforcelltherapynow.org/

About the Regenerative Medicine Foundation

The non-profit Regenerative Medicine Foundation (RMF) fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honoring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives. STEM CELLS Translational Medicine is RMF's official journal partner. See https://www.regmedfoundation.org/

View original content:http://www.prnewswire.com/news-releases/msc-therapy-for-acute-respiratory-distress-syndrome-its-time-to-accelerate-clinical-trials-for-covid-19-patients-in-need-301070329.html

SOURCE Alliance for Cell Therapy Now

Read more:
MSC Therapy for Acute Respiratory Distress Syndrome; It's Time to Accelerate Clinical Trials for COVID-19 Patients in Need - P&T Community

GC027 Shows Promise as Therapy for Adult Relapsed, Refractory T-Cell ALL – Hematology Advisor

GC027,the first humanized chimeric antigen receptor (CAR)-T cell therapy for relapsed/refractoryT-cell acute lymphoblastic leukemia (T-ALL) in adults, appears to be botheffective and have a manageable safety profile, according to research presentedduring the ASCO20 Virtual Scientific Program.

Mortalityrates are high in relapsed/refractory T-ALL, necessitating novel treatments toimprove survival. CD7, a T-cell antigen expressed in more than 95% of diseasesamples, represents a plausible target in this setting. GC027, which targetsCD7 and was developed using using lentivirus and CRISPR/Cas9, showed promise inmurine models for treating T-ALL.

For this single-arm, open-label study, researchers evaluated the safety and efficacy of GC027 in relapsed/refractory T-ALL. All included patients were between 18 and 70 years old, had a projected survival of more than 3 months, and had a performance status of 0 to 2. Patients with extramedullary disease or central nervous system involvement were not eligible to participate.

Fivemen (median age, 24 years) were enrolled in the trial. The median number ofprior lines of therapy was 5, no patients had undergone prior stem celltransplantation, and the median baseline bone marrow tumor burden was 38.2%.

All5 patients had a complete response or complete response with incomplete hematologicrecovery, and 4 of the 5 patients were minimal residual diseasenegative.

Allpatients also experienced grade 3 (4 patients) or 4 (1 patients) cytokinerelease syndrome; no grade 5 events of any kind were reported.

Witha single infusion of GC027, 80% of the patients had robust CAR-T cell expansionand achieved persistent [minimal residual diseasenegative complete response]without using any biologics as part of the preconditioning therapy or bridgingto [hematopoietic stem cell transplantation], the authors wrote.

Wang X, Li S, Gao L, et al. Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(suppl): abstr 3013.

Read the rest here:
GC027 Shows Promise as Therapy for Adult Relapsed, Refractory T-Cell ALL - Hematology Advisor

ReNeuron encouraged by progress in stroke and RP treatments – Proactive Investors Australia

What the company does

Human retinal progenitor cells (hRPC)

Human retinal progenitor cells differentiate into components of the retina.

Reneuron has developed the ability to scale up the manufacturing of hRPCs using a patented low-oxygen cell expansion technology.

The hRPC cell therapy candidate is being evaluated in an ongoing phase I/IIa clinical trial in the US in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP).

CTX Cells

CTX cell therapy candidate is a treatment for patients left disabled by the effects of a stroke.

Reneurons product is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting with the diseases targeted, without the need for additional immunosuppressive drug treatments.

Data from the Phase II PISCES trial indicated CTX therapy was safe and well-tolerated and produced clinically meaningful and sustained improvement in the level of disability and dependence as well as motor function.

Exosome platform

Exosomes are nanoparticles, released by cells, and contain a number of active proteins and micro RNAs, which are short non-coding RNAs capable of regulating gene expression, that arebelieved to play a key role in cell-to-cell communication.

ExoPr0, Reneurons first CTX-derived exosome therapeutic candidate, has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle

hRPC

's ()human retinal progenitor cells (hRPC) have scored some early success.

A Phase I/II assessment of a very small group of sufferers of a blindness-causing disease called retinitis pigmentosa saw a significant improvement in vision after treatment.

Six months after treatment there was a mean improvement of 18.5per treated eye, with a mean improvement of 12 letters per treated eye after nine months, whereasinexorable disease progression is the norm for this disease.

With a total of 22 patients now treated and the study still ongoing, ReNeuron said the efficacy in subsequent patients was seen but at a lower rate and magnitude, with improvement in visual acuity ranging from +5 to +11 letters in the treated eye threemonths after treatment.

In February, clinicaldata from the PISCES II clinical trial were published in peer-reviewedJournal of Neurology, Neurosurgery, and Psychiatry.

CTX

A peer journal review published in May indicated a CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.

ReNeuron has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can cause functional and behavioural recovery in animal models of ischemic (restriction of blood supply) injury.

The new data showed that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and induce host neurogenesis (the generation of new brain cells) leading to a recovery in behavioural deficits.

Coronavirus

In April, Reneuron said it haddeveloped a line of the human exosomes that can deliver a medically relevant payload: Viral vaccines thatmight help in the fight against coronavirus.

The stem cell specialist added that the disruption from lockdowns would inevitably lead to delays in the recruitment of patients for trials of its treatments for stroke disability and retinitis pigmentosa (RP).

It said it will update on how this will affect the release of top-line data from the two studies once it knows the full impact of the restrictions.

See original here:
ReNeuron encouraged by progress in stroke and RP treatments - Proactive Investors Australia

Early Palliative Care Reduces Anxiety and Depression in Acute Myeloid Leukemia Treatment – Cancer Health Treatment News

Acute myeloid leukemia (AML) often comes on abruptly and is commonly treated with an intensive course of chemotherapy that requires hospitalization for four to six weeks. As with stem cell (bone marrow) transplantation, which entails a similar extended hospitalization, the treatment can cause severe physical and psychological symptoms that can persist for months or years.

With stem cell transplantation, however, one intervention has been shown to improve quality of life: the early introduction of palliative care, evidence-based medical care focused on improving quality of life for people with serious illness. Often confused with end-of-life or hospice care, palliative care can benefit people at any stage of cancer who are facing serious side effects.

Now, according to a study presented at the American Society of Clinical Oncology 2020 virtual meeting, palliative care can greatly benefit people with AMLwhen its introduced at the very beginning of treatment.

In the multi-site randomized trial, 160 people with AML were assigned either to usual care (74) or usual care plus palliative care (86). They were all high-risk AML patients, meaning they were over 60 years old, had an existing blood disorder or had already been treated for AML and it had reoccurred. Those in the palliative care group saw palliative care clinicians at least twice a week throughout their initial hospitalization and during any further rehospitalizations. The study subjects completed several assessments of their symptoms and psychological status over six months.

The palliative care clinicians helped them address physical symptoms, including pain, nausea, fatigue, diarrhea, constipation and insomnia, as well as psychological symptoms, such as anxiety, depression and posttraumatic stress disorder (PTSD). For those who had subsequent hospitalizations, many of whom were facing end-of-life situations, the palliative care team also addressed understanding their illness, identifying individual goals and expectations, making treatment decisions and advanced-care planning.

Those who received palliative care reported better overall quality of life, a lower level of symptom burden, less depression, less anxiety and fewer PTSD symptoms by the end of the second week of treatment. The improvements were sustained over the next six months. The intervention led to a significant improvement in quality of life compared to usual care [and] significant improvement in anxiety symptoms, depression symptoms, as well as PTSD symptoms at week 2, said lead study author Areej El-Jawahri, MD, an oncologist at Brigham and Womens Hospital in Boston.

The palliative care intervention was also associated with a beneficial change in those patients who eventually diedless aggressive interventions at the very end of life. These interventions sometimes cause suffering without extending the quality or quantity of life. In the study, those in the palliative care group were more likely to discuss their end-of-life care wishes with their clinicians and less likely to receive chemotherapy in the last 30 days of life.

Oncologists rarely consultant palliative care for patients with AML, said El-Jawahri, who hopes this study will begin to change that fact. Her conclusion: Palliative care should be considered a new standard of care for patients with AML.

To read the abstract, click here.

To learn more about palliative care, see The New Palliative Care.

Go here to see the original:
Early Palliative Care Reduces Anxiety and Depression in Acute Myeloid Leukemia Treatment - Cancer Health Treatment News

Alternative and Complementary Treatments for Cancer – HealthCentral.com

On this page:BasicsComplementary TreatmentAlternative Treatment EffectivenessSide EffectsCancer Cure ScansDiet and Exercise

Youve seen the headlines about natural medicine trends, from yoga to supplements to diet and exercise fads. When it comes to cancer, you want to know what will help you safely regain your health during treatment and after. But there are loads of competing, sometimes-confusing info to sift through. What can you trust? Well, you can start with us here at HealthCentral: We went to the experts to learn all the science-based truth on complementary care for cancer.

First, lets clarify how cancer comes to be: Cancer occurs when abnormal cells anywhere in your body grow out of control, due to mutations in their DNA. Normal cells divide, age and die predictably, copying DNA as they go. Cancer cells, however, dont follow those rules. Rather than die off, they mutate, replicate, and form tumors.

Whats known as the primary site of your cancer is the spot where these cells start growing, and that organ or area determines the type of cancer you have. When cancerous cells journey through your blood or lymphatic system (the network of tissues and organs that flush out toxins, waste, and other undesirables), the areas they invade are metastatic sites.

Note that a cell can be abnormal without being cancerous (also known as malignant). It could be benign (not cancer), or precancerous or premalignant (likely to become cancer). Through screening and testing, docs can determine exactly what youre dealing with.

That depends on what kind of cancer you have, what stage its in, and other factors. Treatment can include:

Doctors often try more than one treatment, spaced out over weeks and months, as they gauge how your body responds. Your doc might even start you on multiple treatments at the same time.

Youve probably heard of complementary care. Or maybe you know it as alternative care. You know a bit of what these treatments might include (youre thinking meditation, herbs, and maybe yoga?). But did you know that while complementary and alternative care are often lumped together (as CAM, Complementary and Alternative Medicine), theyre not the same?

Complementary medicine is used in addition to conventional cancer care. It can include products, practices, and healthcare systems outside of mainstream medicine. These methods dont cure cancer, but work in conjunction with conventional cancer treatments to help in a variety of ways, including pain management and emotional support. Many complementary medicine practices can be considered evidence-based medicine (scientifically studied in randomized controlled trials, the highest level of evidence that guides cancer care).

When complementary medicine works harmoniously with conventional medicine, its an approach known as integrative medicine, or integrated care, where physicians treat you holisticallymeaning caring for you as a whole patient, taking into account all facets of your cancer experience. These can include:

When integrative medicine is administered to treat cancer, its known as integrative oncology, a patient-centered, evidence-informed field of cancer care. It may include:

Alternative medicine, in contrast, is used in place of conventional medicine. Rather than going hand-in-hand with, say surgery and chemo, alternative medicine is done instead of those evidence-based cancer treatments.

A quick note: before you try any new approach during (and after) your cancer treatment journey, make sure to discuss it with your doctor.

If youve used or are considering using complementary medicine as a cancer patient, youre not alonea national survey found that 65% of respondents whod been diagnosed with cancer had used some form of it.

Theres good reason to explore complementary care if you have cancer. It can be part of your supportive carehelping where you need it, like soothing and calming your mind and body as you go through this challenging time. Indeed, research suggests that complementary medicine can assist by:

There are easily hundreds of complementary treatments for cancer, so weve selected a small sample to discuss here. Possibilities include:

Acupuncture: Theres substantial evidence that this ancient Chinese practice of using sterile needles to stimulate different areas of the body can help manage cancer treatment-related nausea and vomiting. It may also help relieve cancer pain and other symptoms, but theres not enough evidence yet to support that.

Herbs: Ginger, for instance, has been shown to help control nausea from chemotherapy when used with conventional anti-nausea medications. Just keep in mind that any supplements you consume can change your body physiologicallynothing you ingest is without the potential for adverse effects. For instance, herbs can impact blood sugar levels and the bloods ability to clot.

Massage therapy: Sure, it feels sublime, and it turns out to have additional benefits too: research suggests that massage therapy can help relieve some cancer symptoms including:

Just be careful not to have deep tissue massage near surgery sites, tumors, or any medical devices. And always tell your therapist about your cancer diagnosis.

Meditation: Mindfulness-based meditation has been shown to improve quality of life during treatment. How? Studies of cancer patients have revealed the following happiness-boosting benefits:

Supplements: Herbal supplements for cancer could potentially help manage side effects like nausea and vomiting, pain, and fatigue, but more scientific evidence is required to make safe decisions about the use of these supplements.

Yoga: Preliminary data of this ancient mind/body practice from India suggests that those who do yoga could see improvements in these areas:

Another benefit: It might help lessen fatigue in breast cancer patients and survivors. More study into the myriad benefits of yoga is needed.

Other approaches: These include hypnosis, relaxation therapy, and biofeedback, all of which might help manage cancer symptoms and treatment side effects, based on study results.

One thing to note about all of these approaches: they might not be covered by your health insurance. According to the American Cancer Society, major insurers, including Blue Cross and Medicare, are starting to cover some complementary treatments. On the list above, acupuncture is most commonly covered. Contact your insurer to see what complementary treatments, if any, are paid for. They might be able to direct you to local providers who are covered under your plan.

When the treatments we discussed earlier (and the hundreds of others that are offered) are used in place of conventional medicine, its known as an alternative treatment. Nearly 40%, or 4 out of 10 Americans, believes that cancer can be cured by alternative treatments, a 2018 survey of cancer patients and people without cancer, found. However, while research shows that complementary medicine can play an important role in conventional cancer medicine, the same hasnt been readily found for alternative treatment.

Case in point: in 2009, the Society for Integrative Oncology (the leading international organization for healthcare professionals and researchers working in the field of complementary therapies in cancer care) published guidelines for healthcare professionals when using complementary medicine.

The org reminded healthcare professionals and patients that unproven cancer treatment methods shouldnt be used in place of conventional options because delaying cancer treatment thats evidence-based and shown to work reduces the chance of remission/cure for cancer patients.

Its important to talk with your healthcare professionals about the risks of using alternative therapies so you can make an informed decision about whats best for your health.

There are definite side effects with CAM. You might think that because something is natural, its safe. But this isnt always the case. Arsenic is natural, for instance, but you wouldnt want to start taking it in large doses.

Another example: Chemotherapy has a multitude of side effects because it destroys both cancerous cells and healthy cells. Its been cited by many as harmful because its made from chemicals. But did you know, some forms of chemo come from nature? Three drugs (Vincristine, Vinblastine, and Vinorelbine) are derived from plant alkaloids and are made from the periwinkle plant (Catharanthus Rosea). Chemo drugs called taxanes (Paclitaxel and Docetaxel) come from the bark of the Pacific Yew tree (Taxus).

Know too that just because something is sold, doesnt mean its been vetted or approved for usefor safety or qualityby the U.S. Food and Drug Administration (FDA). The FDA doesnt regulate vitamins and supplements, so the onus is on us to do our best to source safe, trustworthy products.

Its vital to tell your cancer healthcare team about every treatment and therapy youre using for your cancer, whether its receiving acupuncture for nausea, going to the chiropractor for pain, adding St. Johns Wort to your supplement regime to help manage depression, or getting a massage to feel better.

If youre reluctant to be open with your doc, youre not alone: 29% of cancer patients did not disclose their CAM practices to their providers, according to one study. Secret-keeping could be downright dangerous. Lets use these four seemingly innocuous examples to illustrate why:

Being open with your doc--both before you start a complementary treatment and while youre on it--is key to helping it complement, rather than detract, from the conventional care youre receiving.

When you have cancer, you of course want a cure (as quickly and painlessly as possible, please). But that desire can leave you vulnerable to fake claims, especially in the alternative medicine space. Both the FDA and the Federal Trade Commission (FTC) regularly warn the public about fraudulent cancer treatments.

It can be hard to spot the signs of snake oil. Without a medical degree, how can you be wise to empty promises? Youll often see the same language used in cancer CAM scams, according to the FDA. These phrases should raise a red flag that a treatment is just too good to be true:

Heres how you can protect yourself while receiving evidence-based integrated care:

You might be wondering now: with all this talk of complementary and alternative medicine, what about food? And diet? And exercise? What role does it play in all this? Is there a cancer diet that could be a complementary treatment?

Turns out, theres a strong body of evidence that a healthy diet and regular physical activity are associated with a reduced risk of cancer. The scientific literature links nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. Even after a cancer diagnosis, by making smart choices about what they put on their plate, patients can:

Food has power. To wield it, the American Institute for Cancer Research and American Cancer Society recommends you:

As for physical activity? While you should talk to your healthcare team about what kind and amount of exercise is safe during treatment, The American College of Sports Medicine (ACSM) has issued guidelines for physical activity for cancer survivors, suggesting 150-300 minutes per week of moderate to vigorous physical activity. Exercise is a real magic pill, helping to:

As you can imagine, all of these benefits that come along with being active are particularly important when youre trying to put cancer behind you. Resistance training, in particular, has been proven to improve:

Exercise, like so many CAM options, can help you both feel stronger and respond to treatment better. Just as with other types of complementary treatments, youll want to talk to your doc about how to integrate it, so you can reap the maximum benefits both from your lifestyle changes and your conventional cancer treatment.

Researchers have found that a healthy diet is associated with a reduced risk of cancer. Even if you have cancer, it can help lessen the impact of side effects and improve your quality of life. Studies link nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. All to say that food matters.

Heres the thing: there are therapies that can help you go into remission (the period when your signs and symptoms of cancer are reduced). And some healthcare professionals consider cancer cured if it hasnt returned after five years (also called complete remission). Treatments that achieve a complete remission/cure can include therapies that come from a natural source, like some forms of chemo, which are derived from plant alkaloids. But anyone promising a natural cure for cancer that doesnt have evidence to back up that claim is likely pedaling bunk.

As weve discussed, herbs can be excellent complementary treatment in oncology for things like nausea, but any claim of curing cancer should be tempered by evidence-based medicine results (meaning, proof to back up those claims).

The American Academy of Dermatology warns that black salve isnt as safe as you might think, stating that it has never been proven to work. An article on the AADs website cites reports of bad outcomes for people who tried to treat their cancer (including melanoma) using black salve. The U.S. Food and Drug Administration (FDA) warns against products that are touted as cures for cancer without evidence: The FDA urges consumers to steer clear of these potentially unsafe and unproven products and to always discuss cancer treatment options with their licensed health care provider.

Link:
Alternative and Complementary Treatments for Cancer - HealthCentral.com

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -…

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Wei Li as acting Chief Scientific Officer (CSO), effective June 1, 2020.

During her biotech career, Dr. Li co-founded two companies and built up extensive expertise in all aspects of drug research and development, including preclinical development and pharmacology, clinical development and operations, regulatory affairs, biomarker development and biomanufacturing.

Most recently, Dr. Li was Chief Development Officer at OliX Pharmaceuticals, a leading public South Korean biotech company developing siRNA therapeutics for multiple indications. She also served as Executive Vice President, Product Development at Boston Biomedical, Inc (BBI) from 2007-2018, playing a key role in growing it from a start-up in 2007 to an industry leader in cancer stem cell research, including through the acquisition by Sumitomo Dainippon in 2012. Dr. Li led the development of napabucasin (BBI608), a first-in-class drug selected as one of the worlds top ten cancer drugs in late stage clinical development by Fierce Biotech. Dr. Li started her career at ArQule, a public biotech company developing targeted therapies for hematological malignancies and acquired by Merck &Co in 2019.

Wei Li holds a PhD in Molecular Virology from Georgia State University and completed her Postdoctoral Training at Harvard Medical School.

Dr. Wei Li said: I am thrilled to be joining the great team of scientists and entrepreneurs at Cytovia Therapeutics. NK-cell based therapeutics are at an inflection point. Initial clinical trials have shown promising safety and efficacy. Off-the-shelf manufacturing promises broader and faster patient access. Cytovia Therapeutics has an excellent iPSC CAR-NK platform and a strong pipeline in both hematological and solid tumors. It is tremendously exciting to be involved in this stage of the companys development.

Dr Daniel Teper, co-founder, Chairman and CEO of Cytovia Therapeutics, Inc said: We are delighted to welcome Dr. Wei Li to Cytovia Therapeutics as Chief Scientific Officer. Wei has a stellar track record of bringing innovative oncology drugs from discovery to clinical development. Her operational excellence and entrepreneurial drive will be critical to help bring multiple iPSC CAR NK therapeutics to initial clinical trials starting in 2021.

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem and Macromoltek.

Learn more at http://www.cytoviatx.com

Contact for media enquiries at Cytovia Therapeutics, IncSophie BadrVP corporate AffairsSophie.badre@cytoviatx.com1(929) 317 1565

Read the original:
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -...